After years of stagnation, a paradigm shift has occurred in the therapy of hepatobiliary malignancies: immune-oncology based combinations and new options in the second line revolutionized the treatment of patients with hepatocellular carcinoma, while biliary cancers – endowed with a genuinely high frequency of targetable lesions – evolved as a role model for precision oncology. These developments have generated a growing need for clinicians, pathologists and translational scientists to gain an in-depth understanding of diagnostic and clinical strategies that facilitate the implementation of individualized treatment concepts in hepato-oncology. The EASL school on “Personalized medicine in hepatobiliary malignancies” transitions fluently between molecular pathology diagnostics and clinical translation and provides room and space to foster interdisciplinary exchange. Under the guidance of experts in the field (liver pathologists, clinical and basic hepato-oncologists), students will gain confidence in the interpretation of molecular diagnostics reports and perform group work to build innovative treatment concepts for patients with hepatobiliary cancers. In addition to short lectures, panel discussions and a “live microscopy session”, the school features thought-provoking discourses on the diagnostic and therapeutic future of hepato-oncology.